Baicalein is a novel TLR4-targeting therapeutics agent that inhibits TLR4/HIF-1α/VEGF signaling pathway in colorectal cancer

Abstract

In our study, molecular docking showed that baicalein directly bound to TLR4 protein (binding energy -6.6 kcal/mol), which was the same as the binding energy between TLR4 and TAK242.1 Three-dimensional ribbon model of the baicalein-TLR4 complex showed that hydrogen bonds were formed between the backbone of TLR4 at PHE-573, ALA-572, VAL-548, GLN-547, VAL-524, PHE-500, THR-499, VAL-475 (Figure 1A), and the system was stable during simulation (Figure 1B). The anti-angiogenic effect of baicalein was also demonstrated by the reduced blood vessel formation in the chick yolk sac membrane (Figure 3J), reduced vessel sprouting in the rat aortic ring model (Figure 3K), and cultured human vascular endothelial cells (Figure 3L). Currently, TLR4 antagonists designed based on the modification of the lipid A4 structure,9 the LPS innermost region, may not have potent inhibitory effect because NMR study shows that the presence of the fatty acyl chain of the lipid A moiety is not necessary for driving TLR4 activation.10 In conclusion, we report the discovery that baicalein directly binds to TLR4 and inhibits TLR4/HIF-1α/VEGF signaling pathway in CRC.

Dear Editor,

Toll-like receptor 4(TLR4) is a rational therapeutic target. We have discovered that baicalein directly binds to TLR4, which is a strategy to inhibit TLR4 activity. In our study, molecular docking showed that baicalein directly bound to TLR4 protein (binding energy -6.6 kcal/mol), which was the same as the binding energy between TLR4 and TAK242.¹ Three-dimensional ribbon model of the baicalein-TLR4 complex showed that hydrogen bonds were formed between the backbone of TLR4 at PHE-573, ALA-572, VAL-548, GLN-547, VAL-524, PHE-500, THR-499, VAL-475 (Figure 1A), and the system was stable during simulation (Figure 1B). Surface plasmon resonance study showed a dose-dependent interaction between baicalein and TLR4 protein, with the maximum response of 598 RU (Figure 1C–E). The KD for baicalein binding to TLR4 protein was 9.324 × 10^-5 M, suggesting a direct binding between them. Bio-layer interferometry also showed an interaction between baicalein and TLR4 protein, the binding signal increased with increasing concentrations of baicalein (Figure 1F). The association constant for the binding was 27.3 M^–1s^–1, the dissociation constant was 2.14 × 10^–2s^–1, equilibrium dissociation constant was 7.84 × 10^–4 M, which revealed a direct and stable binding between baicalein and TLR4 protein.

[IMAGE OMITTED. SEE PDF]

Given the well-known pathological roles of TLR4 in CRC,² we used CRC cells as model for the study. Physical interaction between baicalein and TLR4 protein in CRC is suggested by a large thermal shift (∆T_m) of TLR4 as indicated in the melting curve in the cellular thermal shift assay (Figure 1G). More importantly, binding of baicalein to TLR4 interrupted the binding of FITC-conjugated LPS (Figure 1H), and hence inhibited TLR4 activity as demonstrated by the reduced phosphorylation of NF-κB-p65 and Akt upon LPS challenge (Figure 1I). Subsequently, inhibiting TLR4 activity reduced CRC cell viability (Figure 1J,K; Figure S1A,B), which was abolished when TLR4 was overexpressed in the cells (Figure S2A,B; Figure 1L-Q). The reduced NF-κB activity is unlikely due to TLR4, MyD88, and TIRAP because baicalein did not significantly affect their expressions (Figure S3).

We next performed drug-targets-disease network analysis and constructed protein-protein interaction (PPI) network to explore the TLR4 downstream signaling molecules that mediated the inhibitory effects of baicalein. The network showed 18 yellow nodes representing the overlapped targets between CRC and baicalein, and 64 green nodes representing the target-related pathways (Figure 2A). PPI highlighted 16 nodes representing the candidates that mediated the baicalein anti-CRC effects (Figure 2B). Among these, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF-A) were separately linked to 10 to 11 other proteins (Figure 2C). It has been reported that HIF-1α and VEGF expressions are elevated in 54.93% and 56.34% of the CRC patients, respectively, and the expression levels are correlated with tumor stages and overall survival.³ Interestingly, our data showed that HIF-1α and VEGF are the downstream signaling molecules of TLR4. TLR4 overexpression increased HIF-1α and VEGF expressions in CRC cells (Figure 2D,E), whereas TLR4 knockout (Figure 2F) significantly reduced their expressions (Figure 2D). Activation of TLR4 increased HIF-1α and VEGF expressions, which were reversed by baicalein or C34 (Figure 2G,H). Baicalein or C34 also reduced HIF-1α and VEGF basal levels in the cells (Figure 2I,J), which was abolished when TLR4 was overexpressed (Figure 2K,L). In TLR4-knockout cells, baicalein failed to affect HIF-1α and VEGF expressions (Figure 2M,N).

[IMAGE OMITTED. SEE PDF]

HIF-1α plays a crucial role in cancer metastasis.⁴ Our data showed that reduced HIF-1α expression under baicalein treatment inhibited CRC cell migration, which was abolished when TLR4 was overexpressed (Figure S4).

In CRC-bearing xenograft mouse model, baicalein significantly inhibited tumor growth, which was comparable with TAK242 (Figure 3A-C). The treatments did not significantly affect body weight, and the blood levels of alanine aminotransferase, aspartate transaminase, creatine kinase, and urea in these mice (Figures S5), suggesting the treatments do not have apparent toxicity. Interestingly, baicalein significantly inhibited NFκB phosphorylation in the tumors (Figure 3D), the treatment did not affect NFκB and TLR4 expressions (Figure 3D,E). The reduced tumor size was likely due to the reduced cancer growth as indicated by the reduced expression of Ki67 (Figure 3F). More importantly, baicalein reduced the metastatic markers VEGF, CD31, and MMP-2 in the tumor tissues (Figure 3G-I). The anti-angiogenic effect of baicalein was also demonstrated by the reduced blood vessel formation in the chick yolk sac membrane (Figure 3J), reduced vessel sprouting in the rat aortic ring model (Figure 3K), and cultured human vascular endothelial cells (Figure 3L).

[IMAGE OMITTED. SEE PDF]

Our data show that baicalein directly binds to TLR4, interrupts the formation of the complex (LPS.MD-2.TLR4)₂, and inhibits TLR4 activity, hence reduces HIF-1α and VEGF expressions, subsequently inhibits CRC growth, angiogenesis, and reduces the cancer metastatic potential.

Metastatic CRC presents in 25% of the patients at diagnosis, one-third of the patients experience a metastatic relapse after initial curative surgical treatment.^5,6 The binding of baicalein to TLR4 that inhibits the HIF-1α/VEGF signaling pathway holds a promising therapy for metastatic CRC treatment. In the further, we would use target delivery system such as nanoparticles⁷ or aptamers⁸ to deliver baicalein to the tumor site that can further enhance its anti-CRC effect.

The direct binding of baicalein to TLR4 has an added advantage in inhibiting TLR4 activity. Currently, TLR4 antagonists designed based on the modification of the lipid A4 structure,⁹ the LPS innermost region, may not have potent inhibitory effect because NMR study shows that the presence of the fatty acyl chain of the lipid A moiety is not necessary for driving TLR4 activation.¹⁰

In conclusion, we report the discovery that baicalein directly binds to TLR4 and inhibits TLR4/HIF-1α/VEGF signaling pathway in CRC. Our data strongly support the translation of baicalein into novel TLR4-targeting therapeutics for CRC treatment.

ACKNOWLEDGEMENTS

This work was partially supported by SZSTI - Shenzhen Virtual University Park (SZVUP) Special Fund Project #2021Szvup131, ITC (PRP/015/19FX), GDNSF (2018A0303130122, 2021A1515010655), FNRA-IG (RC-FNRA-IG/20-21/SCM/01), NSFC (82074019, 81703705), Characteristic Innovation Projects of Universities in Guangdong Province (2020KTSCX030).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

References

Takashima K, Matsunaga N, Yoshimatsu Y, et al. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Brit J Pharmacol. 2009; 157 (7): 1250-1262.

Yesudhas D, Gosu V, Anwar MA, Choi S. Multiple roles of toll-like receptor 4 in colorectal cancer. Front Immunol. 2014; 5 : 334.

Cao D, Hou M, Guan YS, et al. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009; 9 : 432.

Kang G, Pyo JS, Kim NY, Kang DW. Clinicopathological significances of tumor–stroma ratio (TSR) in colorectal cancers: prognostic implication of TSR compared to hypoxia-inducible factor-1α expression and microvessel density. Curr Oncol. 2021; 28 (2): 1314-1324.

Cutsem EV, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27 (8): 1386-1422.

Engstrand J, Stromberg C, Nilsson H, et al. Synchronous and metachronous liver metastases in patients with colorectal cancer—towards a clinically relevant definition. World J Surg Oncol. 2019; 17 (1): 228. [DOI: https://dx.doi.org/10.1186/s12957-019-1771-9]

Kwan HY, Xu Q, Gong R, et al. Targeted Chinese medicine delivery by a new family of biodegradable pseudo-protein nanoparticles for treating triple-negative breast cancer: in vitro and in vivo study. Front Oncol. 2021; 10 : [eLocator: 600298].

Shigdar S, Schrand B, Giangrande PH, de Franciscis V. Aptamers: cutting edge of cancer therapies. Mol Ther. 2021; 29 (8): 2396-2411.

Peri F, Calabrese V. Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update. J Med Chem. 2014; 57 (9): 3612-3622.

Yu L, Phillips RL, Zhang D, et al. NMR studies of hexaacylated endotoxin bound to wild-type and F126A mutant MD-2 and MD-2.TLR4 ectodomain complexes. J Biol Chem. 2012; 287 (20): 16346-16355.